STING1 and cancer: However, immune checkpoint blockade has demonstrated sustained efficacy in only a limited subset of cancer patients, with many experiencing tumor recurrence after initial responses.[8, 9] Furthermore, the efficacy of PD‐L1 antibodies is significantly limited by their rapid degradation and clearance via the reticuloendothelial system (RES) following systemic administration.[10, 11] This underscores the urgent need for an intelligent delivery platform capable of effectively activating the STING pathway while circumventing tumor immunosuppression.